Moreover, it has been shown that the combination of anti-LAG3 and anti-PD1 monoclonal antibodies enhances IFNγ production and T cell cytotoxicity, leading to more effective tumor growth inhibition (Figure 6) (145). Here, LAG3 is linked to neoplasm.